JDD Buzz Series | Topical Nonsteroidal Therapies for Atopic Dermatitis
Topical corticosteroids have been a mainstay of frontline therapy for atopic dermatitis (AD) for more than half a century. Now therapeutic advances are challenging that standard of care. Nonsteroidal topicals -- topical JAK inhibitors, aryl hydrocarbon receptor agonists, and PDE-4 inhibitors -- are expanding pathways of addressing the signs and symptoms of AD.
An article in the March Journal …
Topical corticosteroids have been a mainstay of frontline therapy for atopic dermatitis (AD) for more than half a century. Now therapeutic advances are challenging that standard of care. Nonsteroidal topicals -- topical JAK inhibitors, aryl hydrocarbon receptor agonists, and PDE-4 inhibitors -- are expanding pathways of addressing the signs and symptoms of AD.
An article in the March Journal … Continue reading "JDD Buzz Series | Topical Nonsteroidal Therapies for Atopic Dermatitis"
The March issue of the Journal of Drugs in Dermatology (JDD) gathers a timely, practice‑oriented collection of studies and reports selected as this month’s Editor’s Picks — spanning potential disease‑modifying implications of antiviral therapy, long‑term biologic data, evolving topical and systemic options for inflammatory skin disease, and a range of hair‑ and nail‑focused investi … 
When a patient reveals they went online for health information, it’s tempting for a clinician to inwardly groan. Fears of self-diagnosis or misinformation about diagnosed conditions can make clinicians concerned when patients seek medical information through online forums and social media. Yet these virtual communities are incredibly popular, most notably Reddit and its discussion forums.
A … 
Welcome to "JDD February 2026 Issue Highlights," your quick tour of this month’s Editor’s Picks from the Journal of Drugs in Dermatology, curated by the Next Steps in Derm Team. This issue pairs practical algorithms, novel therapeutics, real‑world effectiveness data, equity analyses, and procedural reports, all with immediate clinical relevance.
Explore this month’s top picks below:
… 
GLP-1 receptor agonists are an increasingly popular treatment for type 2 diabetes and obesity. Additionally, some dermatologists are finding success with treating psoriasis and hidradenitis suppurativa with GLP-1s independent of an impact on weight loss. As GLP-1 use becomes even more common in medicine, it’s important to understand side effects, including skin effects that could lead GLP-1 pati …